期刊文献+

注射用左泮托拉唑钠的制备与质量控制 被引量:2

Preparation and Quality Control of(L)-pantoprazole Sodium for Injection
下载PDF
导出
摘要 目的制备注射用左泮托拉唑钠,并制定其质量控制方法和相关标准。方法结合制剂的外观和稳定性,筛选冻干支持剂的种类和用量及依地酸二钠的用量,采用高效液相色谱法测定主药的含量及有关物质。结果选用2%(W/V)甘露醇作为冻干支持剂,0.1%(W/V)依地酸二钠作为金属络合剂,左泮托拉唑钠在36~84μg·mL^-1浓度范围内线性关系良好,平均回收率为99.54%,RSD=1.48%(n=9)。结论该制备工艺合理,质量控制方法简便、易行,制备的注射用冻干灭菌粉末能够满足制剂学及临床需要。 Objective To prepare and control the quality of (L)-pantoprazole sodium for injection. Methods The kinds and quantity of frozen-dried supporting agent were screened based on the external apperance and stability, and the quantity of disodium edetate was screened according to the stability. The content of (L)-pantoprazole sodium and related substances were determined by HPLC. Results Mannitol 2% (W/V) and 0.1% (W/V) disodium edetate were used as frozen-dried supporting agent and metal ion chelation agent respectively. A good linear relationship was obtained in the range of 36 - 84 μg·mL^-1, the average recovery of sample was 99.54%, and RSD was 1.48% (n = 9). Conclusion The preparation technics is appropriate and the quality control method is simple and feasible. The prepared frozen-dried injection is able to meet both the pharmaceutical and clinical requirements.
出处 《医药导报》 CAS 2006年第3期236-238,共3页 Herald of Medicine
关键词 左泮托拉唑钠 高效液相色谱法 制备 (L)-pantoprazole sodium HPLC Preparation
  • 相关文献

参考文献4

二级参考文献32

  • 1[1]Kromer W, Kohl B. Pantoprazole sodium [J]. Drugs of the Future, 1990,15(8):801-804.
  • 2[2]Kromer W, Postius S, Riedel R, et al. Pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions [J]. J Pharmacol Exp Therap, 1990, 254:129.
  • 3[3]Doyle E, Mcdowall RD, Murkitt GS, et al. Two systems for the automated analysis of drugs in biological fluids using high-performance liquid chromatography [J]. J Chromatogr, 1990, 527:67-77.
  • 4[1]Anonymous. Pantoprazole--a third pump inhibitor[J]. Drug Ther Bull, 1997,35(2):93-94.
  • 5[2]Sachs C. Proton pump inhibitors and acid-related disease[J]. Pharmaco Therapy, 1997,17(1):22-37.
  • 6[3]Bliesath H, Huber R, Hartmaun H, et al. Dose linearity of the phar-macokinetics of the new H+/K+-ATPase inhibitor pantoprazole after single intravenous administration [J]. J Clin Pharmacol Ther, 1996,34(Suppl 1):18-24.
  • 7[4]Huber R, Hartmaun M, Bliesath H, et al. Pharmacokinetics of panto-prazole in man[J]. J Clin Pharmacol Ther, 1996,34((Suppl 1): 7-16.
  • 8[5]Wurzer H, Sohutze K, Bethke T, et al . Efficacy and safety of panto-prazole in patients with gastroesophageal reflux disease using in intravenous-oral regim[J]. Hepatogastroent, 1999,46:1809-1815.
  • 9[6]Paul J, Metz D, Marton P, et al. Pharmacodynamic equivalence of oral and iv pantoprazole in GERD patients[J]. Am J Gastroenterol, 1998,93:1622, Abstract.
  • 10[7]Metz D C, Forsmark C E, Soffer E, et al. Zollinger-Ellison syndrome patients can replace oral proton pump inhibitors with intravenous pantoprazole without losing control of acid output[N]. Paper Presented at Digestive Disease Week. 1999-05-16(19).

共引文献35

同被引文献11

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部